Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants

Journal of Medicinal Chemistry

Volumn 55, Issue 7, 2012, Pages 3021-3026

  Kazmierski, Wieslaw M ^a   Hamatake, Robert ^a   Duan, Maosheng ^a   Wright, Lois L ^a   Smith, Gary K ^a   Jarvest, Richard L ^b   Ji, Jing Jing ^a   Cooper, Joel P ^a   Tallant, Matthew D ^a   Crosby, Renae M ^a   Creech, Katrina ^a   Wang, Amy ^a   Li, Xianfeng ^c   Zhang, Suoming ^c   Zhang, Yong Kang ^c   Liu, Yang ^c   Ding, Charles Z ^c   Zhou, Yasheen ^c   Plattner, Jacob J ^c   Baker, Stephen J ^c   Bu, Wei ^c   Liu, Liang ^c   more..

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZETIDINE; BOCEPREVIR; DANOPREVIR; DIFLUOROAZETIDINE; HEPATITIS C VIRUS PROTEASE INHIBITOR; PIPERIDINE; PROTEINASE INHIBITOR; SIMEPREVIR; TELAPREVIR; UNCLASSIFIED DRUG; UREA; VANIPREVIR;

ANIMAL EXPERIMENT; ARTICLE; DRUG POTENCY; ENZYME ASSAY; HEPATITIS C; HEPATITIS C VIRUS; LIVER CLEARANCE; NONHUMAN; RAT; REPLICON; VIRUS MUTANT;

EID: 84859803083     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201278q     Document Type: Article

References (27)

1. Hepatitis C; Fact Sheet No. 164; World Health Organization: Geneva, Switzerland, June 2011; http://www.who.int/mediacentre/factsheets/fs164/en/ index.html.
2. Njoroge, F. G.; Chen, K. X.; Shih, N. Y.; Piwinski, J. J. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection Acc. Chem. Res. 2008, 41, 50-59
3. Lin, C.; Kwong, A. D.; Perni, R. B. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3/4A serine protease Infect. Disord.: Drug Targets 2006, 6, 3-16
4. Pearlman, B. L. Hepatitis C treatment update Am. J. Med. 2004, 117, 344-352
5. Seiwert, S. D.; Andrews, S. W.; Jiang, Y.; Serebryany, V.; Tan, H.; Kossen, K.; Rajagopalan, P. T.; Misialek, S.; Stevens, S. K.; Stoycheva, A.; Hong, J.; Lim, S. R.; Qin, X.; Rieger, R.; Condroski, K. R.; Zhang, H.; Do, M. G.; Lemieux, C.; Hingorani, G. P.; Hartley, D. P.; Josey, J. A.; Pan, L.; Beigelman, L.; Blatt, L. M. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227) Antimicrob. Agents Chemother. 2008, 52, 4432-4441
6. Raboisson, P.; de Kock, H.; Rosenquist, A.; Nilsson, M.; Salvador-Oden, L.; Lin, T. I.; Roue, N.; Ivanov, V.; WaIhling, H.; WickstroIm, K.; Hamelink, E.; Edlund, M.; Vrang, L.; Vendeville, S.; Van de Vreken, W.; McGowan, D.; Tahri, A.; Hu, L.; Boutton, C.; Lenz, O.; Delouvroy, F.; Pille, G.; Surleraux, D.; Wigerinck, P.; Samuelsson, B.; Simmen, K. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350 Bioorg. Med. Chem. Lett. 2008, 18, 4853-4858
7. McCauley, J. A.; McIntyre, C. J.; Rudd, M. T.; Nguyen, K. T.; Romano, J. J.; Butcher, J. W.; Gilbert, K. F.; Bush, K. J.; Holloway, M. K.; Swestock, J.; Wan, B. L.; Carroll, S. S.; Dimuzio, J. M.; Graham, D. J.; Ludmerer, S. W.; Mao, S. S.; Stahlhut, M. W.; Fandozzi, C. M.; Trainor, N.; Olsen, D. B.; Vacca, J. P.; Liverton, N. J. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor J. Med. Chem. 2010, 53, 2443-2463
8. Flisiak, R.; Parfieniuk, A. Investigational drugs for hepatitis C Expert Opin. Invest. Drugs 2010, 19, 63-75
9. Kwong, A. D.; McNair, L.; Jacobson, I.; George, S. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors Curr. Opin. Pharmacol. 2008, 8, 522-531
10. Chen, K. X.; Njoroge, F. G. A review of HCV protease inhibitors Curr. Opin. Invest. Drugs 2009, 10, 821-837
11. Reiser, M.; Timm, J. Serine protease inhibitors as anti-hepatitis C virus agents Expert Rev. Anti-Infect. Ther. 2009, 7, 537-547
12. White, P. W.; LlinaIs-Brunet, M.; Amad, M.; Bethell, R. C.; Bolger, G.; Cordingley, M. G.; Duan, J.; Garneau, M.; Lagacé, L.; Thibeault, D.; Kukolj, G. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease Antimicrob. Agents Chemother. 2010, 54, 4611-4618
13. Rong, L.; H. Dahari, H.; Ribeiro, R. M.; Perelson, A. S. Rapid emergence of protease inhibitor resistance in hepatitis C virus Sci. Transl. Med. 2010, 2, 30ra32
14. Li, X.; Zhang, Y.-K.; Liu, Y.; Zhang, S.; Ding, C. Z.; Zhou, Y.; Plattner, J. J.; Baker, S. J.; Liu, L; Bu, W; Kazmierski, W. M.; Wright, L.; Smith, G.; Jarvest, R.; Duan, M.; Ji, J. J.; Cooper, J.; Tallant, M.; Crosby, R.; Creech, K.; Ni, Z.; Zou, W.; Wright, J. Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease Bioorg. Med. Chem. Lett. 2010, 20, 7493-7497
15. Ding, C. Z.; Zhang, Y.-K.; Li, X.; Liu, Y.; Zhang, S.; Zhou, Y.; Plattner, J. J.; Baker, S. J.; Liu, L.; Duan, M.; Jarvest, R.; Ji, J. J.; Kazmierski, W. M.; Tallant, M.; Wright, L.; Smith, G; Crosby, R; Wang, A.; Ni, Z.; Zou, W.; Wright, J. Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease Bioorg. Med. Chem. Lett. 2010, 20, 7317-7322
16. Li, X.; Zhang, Y.-K.; Liu, Y.; Ding, C. Z.; Zhou, Y.; Li, Q.; Plattner, J. J.; Baker, S. J.; Zhang, S.; Kazmierski, W. M. Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates Bioorg. Med. Chem. Lett. 2010, 20, 5695-5700
17. Li, X; Zhang, S.; Zhang, Y.-K.; Liu, Y.; Ding, C. Z.; Zhou, Y.; Plattner, J. J.; Baker, S. J.; Bu, W.; Liu, L.; Kazmierski, W. M.; Duan, M.; Grimes, R. M.; Wright, L. L.; Smith, G. K.; Jarvest, R. L.; Ji, J.-J.; Cooper, J. P.; Tallant, M. D.; Crosby, R. M.; Creech, K.; Ni, Z.-J.; Zou, W.; Wright, J. Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties Bioorg. Med. Chem. Lett. 2011, 21, 2048-2054
18. 2 J. Phys. Chem. A 2009, 113, 11028-34
19. Bolognese, A.; Esposito, A.; Manfra, M.; Catalano, L.; Petruzziello, F.; Martorelli, M. C.; Pagliuca, R. An NMR study of the bortezomib degradation under clinical use conditions. Adv. Hematol. 2009, DOI: 10.1155/2009/704928.
20. 50 [nM]): wt = 1.60, A156T = 200, and R155K = 350. Buckman, B. O.; Seiwert, S. D.; Presented at The International Liver Congress 2009, Copenhagen, Denmark, April 22-26, 2009; Poster 938.
21. Le Pogam, S.; Yan, J. M.; Chhabra, M.; Ilnicka, M.; Chin, D.; Ji, Y.; Zhang, Y.; Shulman, N.; Klumpp, K.; Nájera, I. Low Prevalence of Danoprevir Resistance Identified in Genotype 1b HCV Patients with Prior Null Response Treated with Danoprevir plus Low-Dose Ritonavir plus Peginterferon Alfa-2a (40KD)/Ribavirin for 12 Weeks. Presented at the International Liver Congress 2011 [46th Annual Meeting of the European Association for the Study of the Liver (EASL)], March 30-April 3, 2011, Berlin, Germany; Poster 1227.
22. Lenz, O.; de Bruijne, J.; Vijgen, L.; Verbinnen, T.; Weegink, C.; van Marck, H.; Vandenbroucke, I.; Peeters, M.; De Smedt, G.; Simmen, K.; Fanning, G.; Picchio, G.; Reesink, H. Treatment Outcome and Resistance Analysis in HCV Genotype 1 Patients Previously Exposed to TMC435 Monotherapy and Re-Treated with TMC435 in Combination with PegIFNa-2a/Ribavirin. Presented at the International Liver Congress 2011 [46th Annual Meeting of the European Association for the Study of the Liver (EASL)], March 30-April 3, 2011, Berlin, Germany; Poster 2068
23. Lin, T. I.; Lenz, P.; Fanning, G.; Verbinnen, T.; Delouvroy, F.; Scholliers, A.; Vermeiren, K.; Rosenquist, Ã ; Edlund, M.; Samuelsson, B.; Vrang, L.; de Kock, H.; Wigerinck, P.; Raboisson, P.; Simmen, K. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor Antimicrob. Agents Chemother. 2009, 53, 1377-1385
24. Reesink, H. W.; Fanning, G. C.; Abou Farha, K.; Weegink, C.; Van Vliet, A.; Vanat Klooster, G.; Lenz, O.; Aharchi, F.; Marien, K.; Van Remoortere, P. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients Gastroenterology 2010, 138, 913-921
25. Kazmierski, W. M. Boron and Non-Boron-Based HCV NS3/4 Protease Inhibitors: Discovery of a Novel Motif Possessing High Potency against PI-Resistant Mutants. Presented at the 6th Annual Cambridge Healthtech Institute HCV Drug Discovery, San Diego, CA, April 29, 2010.
26. Raboisson, P.; Lin, T.-I.; de Kock, H.; Vendeville, S.; Van de Vreken, W.; McGowan, D.; Tahri, A.; Hu, L.; Lenz, O.; Delouvroy, F. Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 5095-5100
27. Cooper, J. P.; Duan, M.; Grimes, R. M.; Kazmierski, W. M.; Tallant, M. D. Preparation of Macrocyclic Peptides for the Treatment of Viral Infection. WO2010088394, 2010